55532-26-8

Basic information

• Product Name: TIMTEC-BB SBB006359
• Synonyms: TIMTEC-BB SBB006359;(H)-2-(3-Nitrostyryl)pyridine;2-(m-Nitrostyryl)pyridine;2-[(E)-2-(3-Nitrophenyl)ethenyl]pyridine;2-[(E)-2-(3-nitrophenyl)vinyl]pyridine;2-[2-(3-nitrophenyl)ethenyl]pyridine;2-[2-(3-nitrophenyl)vinyl]pyridine;Pyridine, 2-[2-(3-nitrophenyl)ethenyl]-, trans-
• CAS NO: 55532-26-8
• Molecular Formula: C₁₃H₁₀N₂O₂
• Molecular Weight: 226.23
• Mol File: 55532-26-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: TIMTEC-BB SBB006359(CAS DataBase Reference)
• NIST Chemistry Reference: TIMTEC-BB SBB006359(55532-26-8)
• EPA Substance Registry System: TIMTEC-BB SBB006359(55532-26-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 55532-26-8(Hazardous Substances Data)

Upstream product

• 109-06-8 α-picoline 
• 108-24-7 acetic anhydride 
• 99-61-6 3-nitro-benzaldehyde 
• 100-69-6 2-vinylpyridine 
• 585-79-5 m-nitrobromobenzene 
• 645-00-1 m-iodonitrobenzene 

Downstream Products

• 347335-08-4 3-(2-[2]pyridyl-ethyl)-aniline 
• 176034-12-1 3-(trans-2-[2]pyridyl-vinyl)-aniline 
• 1401773-94-1 (E)-3-(1-{4-[3-(2-pyridin-2-ylvinyl)phenylamino]phenyl}-1H-[1,2,3]triazol-4-yl)propan-1-ol 

Relevant articles and documents

A novel D-glucosamine-derived pyridyltriazole@ palladium catalyst for solvent-free Mizoroki-Heck reactions and its application in the synthesis of Axitinib

A green method for the synthesis of a D-glucosamine-derived triazole@ palladium catalyst is described. The synthesized catalyst containing a 2-pyridyl-1,2,3-triazole ligand was prepared via a click route in high yields and was explored in Heck cross-coupling reactions between different aryl halides and olefins under solventfree conditions. The catalyst can be separated from the reaction mixture and reused at least six times with superior activity. In addition, using this protocol, the marketed drug Axitinib (antitumor) could be synthesized easily.

Compounds for use as therapeutic agents affecting p53 expression and/or activity

The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a -NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a -CONR7R8 group, a -SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a -(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a -(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use as an agent for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.